Vaccination

Moderna's coronavirus vaccine found to be 94.5% effective in recent study

The study included 95 cases of COVID-19. Image: REUTERS/Dado Ruvic

Reuters Staff

Share:

Our Impact
The Big Picture
Explore and monitor how Vaccination is affecting economies, industries and global issues
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale

Stay up to date:

Vaccination

Moderna, which went public in 2018, has received nearly $1 billion in research and development funding. Image: REUTERS/Dado Ruvic/Illustration - RC2VZJ9ELV8D

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Related topics:

VaccinationCOVID-19Healthcare Delivery

Share:

Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

Monkeypox vaccines: A virologist answers 6 key questions
About Us
Events
Media
Partners & Members
Language Editions

Privacy Policy & Terms of Service

© 2022 World Economic Forum